A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Vinorelbine|DRUG: Docetaxel
Sponsor: iOMEDICO AG
Collaborators: Arbeitsgemeinschaft fur Internistische Onkologie|Amgen